

Viva Leisure Ltd (VVA)

Rating: Buy | Risk: High | Price Target: \$2.60

Business as Usual So Far, But Multiple Short Term Risks are Heightened

Key Information

Current Price (\$ps)	1.44
12m Target Price (\$ps)	2.60
Target Price Upside (%)	80.6%
TSR (%)	80.6%
Reporting Currency	AUD
Market Cap (\$m)	86.1
Sector	Health Care
Avg Daily Volume (m)	0.0
ASX 200 Weight (%)	0%

Fundamentals


YE 31 Dec (AUD)	FY19A	FY20E	FY21E	FY22E
Sales (\$m)	31.1	54.8	92.2	109.7
NPAT (\$m)	2.9	5.4	9.3	13.1
EPS (cps)	5.4	9.6	15.5	21.9
EPS Growth (%)	(2.1%)	76.4%	61.9%	41.3%
DPS (cps) (AUD)	0.0	0.0	3.8	9.0
Franking (%)	0%	0%	100%	100%

Ratios

YE 31 Dec	FY19A	FY20E	FY21E	FY22E
P/E (x)	50.7	15.0	9.3	6.6
EV/EBITDA (x)	19.1	6.4	4.2	3.5
Div Yield (%)	0.0%	0.0%	2.7%	6.3%
Payout Ratio (%)	0.0%	0.0%	24.7%	41.2%

Price Performance

YE 31 Dec	1 Mth	2 Mth	3 Mth	1 Yr
Relative (%)	(26.1%)	(26.6%)	(32.7%)	n/a
Absolute (%)	(51.4%)	(49.8%)	(54.0%)	n/a
Benchmark (%)	(25.3%)	(23.2%)	(21.3%)	(13.9%)



Price performance indexed to 100

Source:

Major Shareholders

Shja Management	36.1%
Mera Vale No1	15.3%
Bennelong	7.6%
Doma Equities	5.7%
OC Funds	4.8%

Darren Vincent | Senior Analyst

+61 2 9238 1269

dvincent@shawandpartners.com.au

Event

We spoke with VVA management regarding business conditions and its expectations through to June 30. VVA report business remains on track with guidance and that it has not experienced any impact on patronage. Shaw and Partners forecasts and our 12 month TP are brought back to reflect a 4Q20 impact and our expectation that market multiples will take longer than 12 months to recover. Our BUY rating remains unchanged.

Highlights

- **Business as usual so far** - VVA reports its business remains on track with guidance and that it has not experienced any impact on patronage, member cancellations or growth in new signings across its facilities. It continues to run normal promotions without reducing prices, but has stepped up hygiene procedures within its facilities. VVA's monthly sales run rate exiting Dec 2019 was \$4.4m up from \$2.6m at the end of Dec 2018 which all things remaining unchanged provides significant momentum and upside for a full 12 month contribution in 2021. VVA has continued to achieve monthly organic growth since Dec. and has not changed its guidance to run rate growth of 112% for the June 2020 month, however we are now factoring in no growth thru 4Q20. Our relatively conservative downgrade for VVA reflects key business fundamentals highlighted below.
- **The average age of VVA members is 32, insulating it from the key high risk age demographics.** Initial data from the CCDC shows most people under the age of 60 do not die from COVID-19. People under 40 have a 0.2% chance of dying if they contract COVID-19 and there has not been a single mortality of a child under the age of 9, i.e. for most people it appears to be safe to continue participating in leisure activities and VVA's gym membership is relatively cheap at ~\$20 pw.

Age	Death Rate Confirmed cases	Death rate All cases
80+ years old	21.90%	14.80%
70-79 years old		8.00%
60-69 years old		3.60%
50-59 years old		1.30%
40-49 years old		0.40%
30-39 years old		0.20%
20-29 years old		0.20%
10-19 years old		0.20%
0-9 years old		No fatalities

Source: The Chinese CCDC, Chinese Journal of Epidemiology. Data is based on 72,314 confirmed, suspected, and asymptomatic COVID-19 cases in China as of February 11.

- **VVA's regional exposure is expected to insulate it, unlike city gyms exposed to CBD office closures.** VVA's facilities are located in regional suburban/metro rather than CBD locations insulating it from an expected downturn in city gym patronage as CBD offices potentially face closures. We do note however that VVA's CISAC facility at Canberra University is expected to account for 30% of sales in 2020.
- **Multiple short term risks are heightened including:** i) with increased detection of COVID in regional areas patronage reacts at a later stage than in city areas, ii) enforced closure of gyms could be directed by health departments or local governments, iii) the longer the COVID episode continues the greater the chance of cancellations, iv) if infection is traced back to gym facilities it could result in cancellations, and v) VVA does not lock members into 12 month contracts which enables cancellations.

Recommendation


Unlike other discretionary leisure exposures such as the ASX listed travel stocks which are well into significant sales downturns; VVA is reportedly yet to experience any impact. The risk as detailed above is that a possible short term closure could impact sales by more than our downgraded forecasts. We estimate VVA's cash balance post recent acquisitions is now \$12m and with the potential to draw further debt VVA is positioned to acquire cheap assets or cover short term losses. Balancing risk /return we believe it is a relatively low risk exposure yet VVA's share price is off 52% since its February high of \$2.99.

Viva Leisure Ltd
Health Care
Health Care Equipment & Services
FactSet: VVA-AU / Bloomberg: VVA AU

Key Items	Data
Recommendation	BUY
Risk	HIGH
Price (\$ps)	1.44
Target Price (\$ps)	2.60
52 Week Range (\$ps)	-
Shares on Issue (m)	59.8
Market Cap (\$m)	86.1
Enterprise Value (\$m)	85.1
TSR (%)	80.6%
Valuation NPV	Data
Beta	1.50
Cost of Debt (net) (%)	7.9%
Risk Free Rate (%)	4.3%
Terminal Growth (%)	3.0%
WACC (%)	13.8%

Company Description

Viva Leisure Ltd. operates health clubs in health and leisure industries. It offers customers with membership options and a range of facilities from big box to boutique fitness. The firm's brands include Club Lime, Ladies Only, Psyche Life, Aquatics, Hiit Republic, Swim School, Gymmy PT and Studio by Club Lime. The company was founded by Harry Konstantinou and Angelo Konstantinou on January 12, 2004 and is headquartered in Mitchell, Australia Capital Territory.



Financial Year End: 31 December

Investment Summary (AUD)	FY18A	FY19A	FY20E	FY21E	FY22E
EPS (Reported) (cps)	5.5	5.4	8.0	12.2	18.1
EPS (Underlying) (cps)	5.5	5.4	9.6	15.5	21.9
EPS (Underlying) Growth (%)	119.7%	(2.1%)	76.4%	61.9%	41.3%
PE (Underlying) (x)	n/a	50.7	15.0	9.3	6.6
EV / EBIT (x)	n/a	27.5	11.7	8.5	6.2
EV / EBITDA (x)	n/a	19.1	6.4	4.2	3.5
DPS (cps) (AUD)	0.0	0.0	0.0	3.8	9.0
Dividend Yield (%)	n/a	0.0%	0.0%	2.7%	6.3%
Franking (%)	0%	0%	0%	100%	100%
Payout Ratio (%)	0.0%	0.0%	0.0%	24.7%	41.2%
Free Cash Flow Yield (%)	n/a	2.1%	(10.4%)	1.1%	5.6%
Profit and Loss (AUD) (m)	FY18A	FY19A	FY20E	FY21E	FY22E
Sales	24.1	31.1	54.8	92.2	109.7
Sales Growth (%)	16.3%	28.9%	76.4%	68.2%	19.0%
EBITDA	5.2	7.2	13.2	22.6	28.8
EBITDA Margin (%)	21.6%	23.3%	24.1%	24.5%	26.2%
Depreciation & Amortisation	(1.5)	(2.2)	(5.9)	(11.6)	(12.5)
EBIT	3.7	5.0	7.3	11.0	16.3
EBIT Margin (%)	15.2%	16.2%	13.3%	11.9%	14.8%
Net Interest	(0.5)	(1.1)	(0.8)	(0.6)	(0.8)
Pretax Profit	3.1	4.0	6.5	10.4	15.4
Tax	(0.2)	(1.1)	(1.9)	(3.1)	(4.6)
Tax Rate (%)	(7.1%)	(28.2%)	(30.0%)	(30.0%)	(30.0%)
NPAT Underlying	2.9	2.9	5.4	9.3	13.1
NPAT Reported	2.9	2.9	4.5	7.3	10.8
Cashflow (AUD) (m)	FY18A	FY19A	FY20E	FY21E	FY22E
EBIT	3.7	5.0	7.3	11.0	16.3
Tax Paid	0.0	(0.5)	(1.9)	(3.1)	(4.6)
Net Interest	(0.5)	(0.6)	(1.2)	(1.0)	(1.0)
Depreciation & Amortisation	1.5	2.2	5.9	11.6	12.5
Other	(3.0)	1.2	2.4	1.5	0.7
Operating Cashflow	1.7	7.3	12.5	20.0	23.8
Capex	0.0	0.0	(21.0)	(19.0)	(19.0)
Acquisitions and Investments	0.0	(7.1)	(17.0)	0.0	0.0
Disposal of Fixed Assets/Investments	0.1	0.2	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0
Investing Cashflow	0.1	(7.0)	(38.0)	(19.0)	(19.0)
Free Cashflow	(0.2)	3.1	(8.5)	1.0	4.8
Equity Raised / Bought Back	0.0	22.5	19.0	0.0	0.0
Dividends Paid	0.0	0.0	0.0	0.0	(4.8)
Other	0.6	(5.5)	3.4	(3.4)	(6.4)
Financing Cashflow	0.6	17.1	22.4	(3.4)	(11.3)
Net Change in Cash	2.3	17.5	(3.1)	(2.4)	(6.5)
Balance Sheet (AUD) (m)	FY18A	FY19A	FY20E	FY21E	FY22E
Cash	1.1	14.4	11.3	8.9	2.4
Accounts Receivable	0.1	0.2	0.3	0.5	0.6
Inventory	0.1	0.4	0.4	0.4	0.4
Other Current Assets	0.1	0.0	0.0	0.0	0.0
PPE	9.6	19.2	47.1	46.9	45.5
Goodwill & Intangibles	0.0	6.6	5.7	3.7	1.4
Other Non Current Assets	0.3	n/a	n/a	n/a	n/a
Total Assets	11.4	44.2	68.3	63.8	53.7
Accounts Payable	2.0	2.5	2.7	4.0	4.6
Short Term Debt	3.3	2.3	2.3	2.3	2.3
Long Term Debt	4.1	5.7	12.5	14.5	14.5
Income Taxes Payable	0.5	1.5	1.5	1.5	1.5
Other	1.6	6.6	5.3	5.3	5.3
Total Liabilities	11.5	18.5	24.2	27.5	28.1
Total Shareholder Equity	(0.1)	25.8	49.3	56.6	62.5
Ratios	FY18A	FY19A	FY20E	FY21E	FY22E
ROE (%)	(8,489.8%)	22.2%	14.5%	17.5%	22.0%
Gearing (%)	101.1%	(33.3%)	6.5%	12.2%	18.6%
Net Debt / EBITDA (x)	1.2	(0.9)	0.3	0.3	0.5

Rating Classification

Buy	Expected to outperform the overall market
Hold	Expected to perform in line with the overall market
Sell	Expected to underperform the overall market
Not Rated	Shaw has issued a factual note on the company but does not have a recommendation

Risk Rating

High	Higher risk than the overall market – investors should be aware this stock may be speculative
Medium	Risk broadly in line with the overall market
Low	Lower risk than the overall market

RISK STATEMENT: Where a company is designated as ‘High’ risk, this means that the analyst has determined that the risk profile for this company is significantly higher than for the market as a whole, and so may not suit all investors. Clients should make an assessment as to whether this stock and its potential price volatility is compatible with their financial objectives. Clients should discuss this stock with their Shaw adviser before making any investment decision.

Disclaimer

Shaw and Partners Limited ABN 24 003 221 583 (“Shaw”) is a Participant of ASX Limited, Chi-X Australia Pty Limited and the holder of Australian Financial Services Licence number 236048.

ANALYST CERTIFICATION: The Research Analyst who prepared this report hereby certifies that the views expressed in this document accurately reflect the analyst’s personal views about the Company and its financial products. Neither Shaw nor its Research Analysts received any direct financial or non-financial benefits from the company for the production of this document. However, Shaw Research Analysts may receive assistance from the company in preparing their research which can include attending site visits and/or meetings hosted by the company. In some instances, the costs of such site visits or meetings may be met in part or in whole by the company if Shaw considers it is reasonable given the specific circumstances relating to the site visit or meeting. As at the date of this report, the Research Analyst does not hold, either directly or through a controlled entity, securities in the Company that is the subject of this report. Shaw restricts Research Analysts from trading in securities outside of the ASX/S&P100 for which they write research. Other Shaw employees may hold interests in the company.

DISCLAIMER: This report is published by Shaw to its clients by way of general, as opposed to personal, advice. This means it has been prepared for multiple distribution without consideration of your investment objectives, financial situation and needs (“Personal Circumstances”). Accordingly, the advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not the advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of your Shaw client adviser. This report is provided to you on the condition that it not be copied, either in whole or in part, distributed to or disclosed to any other person. If you are not the intended recipient, you should destroy the report and advise Shaw that you have done so. This report is published by Shaw in good faith based on the facts known to it at the time of its preparation and does not purport to contain all relevant information with respect to the financial products to which it relates. The research report is current as at the date of publication until it is replaced, updated or withdrawn. Although the report is based on information obtained from sources believed to be reliable, Shaw does not make any representation or warranty that it is accurate, complete or up to date and Shaw accepts no obligation to correct or update the information or opinions in it. If you rely on this report, you do so at your own risk. Any projections are indicative estimates only and may not be realised in the future. Such projections are contingent on matters outside the control of Shaw (including but not limited to market volatility, economic conditions and company-specific fundamentals) and therefore may not be realised in the future. Past performance is not a reliable indicator of future performance. Except to the extent that liability under any law cannot be excluded, Shaw disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.

DISCLOSURE: Shaw will charge commission in relation to client transactions in financial products and Shaw client advisers will receive a share of that commission. Shaw, its authorised representatives, its associates and their respective officers and employees may have earned previously or may in the future earn fees and commission from dealing in the Company’s financial products. Shaw acted as Co-Manager in the December 2019 placement of VVA securities for which it received fees or will receive fees for acting in this capacity. Accordingly, Shaw may have a conflict of interest which investors should consider before making an investment decision

RESEARCH TEAM: For analyst qualifications and experience, refer to our website at <http://www.shawandpartners.com.au/about/our-people/research>

RESEARCH POLICY: For an overview of our Research policy, refer to our website at <https://www.shawandpartners.com.au/media/1267/researchpolicy.pdf>

If you no longer wish to receive Shaw research, please contact your Financial Adviser to unsubscribe.

Sydney Head Office	Melbourne	Brisbane	Adelaide	Canberra	Perth
Level 7, Chifley Tower	Level 20	Level 28	Level 23	Level 7	Level 20
2 Chifley Square	90 Collins Street	111 Eagle Street	91 King William Street	54 Marcus Clarke Street	108 St Georges Terrace
Sydney NSW 2000	Melbourne VIC 3000	Brisbane QLD 4000	Adelaide SA 5000	Canberra ACT 2600	Perth WA 6000
Telephone: +61 2 9238 1238	Telephone: +61 3 9268 1000	Telephone: +61 7 3036 2500	Telephone: +61 8 7109 6000	Telephone: +61 2 6113 5300	Telephone: +61 8 9263 5200
Toll Free: 1800 636 625	Toll Free: 1800 150 009	Toll Free: 1800 463 972	Toll Free: 1800 636 625	Toll Free: 1800 636 625	Toll Free: 1800 198 003